MaxCyte appoints life-sciences vet as EVP, updates on lead therapy to treat solid tumors – Proactive Investors UK

Posted: December 20, 2019 at 4:49 pm

() CEO Doug Doerfler tells Proactive it has appointed a new executive vice president as it continues with a Phase I trial of its MCY-M11 cancer drug. Doerfler says Shruti Abbato will serve as executive VP of business development for its CARMA cellular therapies, which is aiming to provide faster treatment than existing cancer therapies.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

Read more from the original source:
MaxCyte appoints life-sciences vet as EVP, updates on lead therapy to treat solid tumors - Proactive Investors UK

Related Post

Comments are closed.

Archives